Psychotropic drugs and falls: New evidence pertaining to serotonin reuptake inhibitors

Pharmacotherapy

Volumn 20, Issue 3, 2000, Pages 308-317

  Sleeper, Rebecca ^a   Bond, C A ^b   Rojas Fernandez, Carlos ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESIPRAMINE; DIAZEPAM; DIGOXIN; DIURETIC AGENT; FLUOXETINE; HALOPERIDOL; HYPNOTIC AGENT; HYPNOTIC SEDATIVE AGENT; LORAZEPAM; METOCLOPRAMIDE; MOCLOBEMIDE; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXAZEPAM; PAROXETINE; PSYCHOTROPIC AGENT; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

COGNITIVE DEFECT; DRUG USE; FALLING; FRACTURE; GAIT DISORDER; HEART ARRHYTHMIA; HUMAN; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PHARMACIST; PRESCRIPTION; PREVENTION; REVIEW; RISK FACTOR; VERTIGO; VISUAL DISORDER;

EID: 0034005719     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.4.308.34885     Document Type: Review

References (66)

1. Granek E, Baker S, Abbey H, et al. Medications and diagnoses in relation to falls in a long term care facility. J Am Geriatr Soc 1987;35:503-11.
2. Myers AH, Baker SP, Van Natta ML, et al. Risk factors associated with falls and injuries among elderly institutionalized persons. Am J Epidemiol 1991;133:1179-90.
3. Cumming RG. Epidemiology of medication related falls and Fractures in the elderly. Drugs Aging 1998;12(1):43-53.
4. Tinetti M, Williams C. Falls, injuries due to falls, and the risk of admission to a nursing home. N Engl J Med 1997;337(18):1279-84.
5. Rubenstein L, Josephson K, Robbins A. Falls in the nursing home. Ann Intern Med 1994;121:442-51.
6. Coogler CE, Wolf SL. Falls. In: Hazzard WR, Blass JP, Ettinger WH, Halter JB, Ouslander JG, eds. Principles of geriatric medicine and gerontology, 4th ed. New York: McGraw-Hill, 1999:1535-46.
7. Fox RA, Puxty JAH. Falls. In: Fox RA, Puxty JAH, eds. Medicine in the frail elderly. A problem-oriented approach. Edinburgh: Edward Arnold, 1993:30-5.
8. Kiely D, Kiel DP, Burrows AB, et al. Identifying nursing home residents at risk for falling. J Am Geriatr Soc 1998;46:551-5.
9. Melton LJ, Beard CM, Kokmen E, et al. Fracture risk in patients with Alzheimer's disease. J Am Geriatr Soc 1994;42(6):614-19.
10. Buchner D, Larson E. Falls and fractures in patients with Alzheimer-type dementia. JAMA 1987;257(11):1492-5.
11. Johnell OL, Melton J, Atkinson EJ, et al. Fracture risk in patients with parkinsonism: a population based study in Olmsted County, Minnesota. Age Ageing 1992;21:32-8.
12. Tinetti M, Speechley M, Ginter SF. Risk factors for falls among elderly people living in the community. N Engl J Med 1988;319(26):1701-6.
13. O'Loughlin JL, Robitaille Y, Boivin JF, et al. Incidence and risk factors for falls and injurious falls among community dwelling elderly. Am J Epidemiol 1993;137(3):342-54.
14. Robbins AS, Rubenstein LZ, Josephson KR, et al. Predictors of falls among elderly people. Results of two population based studies. Arch Intern Med 1989;149:1628-33.
15. Herndon JG, Helmick CG, Sattin RW, et al. Chronic medical conditions and risk of fall injury events at home in older adults. J Am Geriatr Soc 1997;45:739-43.
16. Glynn RJ, Seddon JM, Krug JH Jr, et al. Falls in elderly patients with glaucoma. Arch Ophthalmol 1991;109(2):205-10.
17. Tinetti ME, Doucette J, Claus E, Marottoli R. Risk factors for serious injury during falls by older persons in the community. J Am Geriatr Soc 1995;43:1214-21.
18. Whooley MA, Kip KE, Ensrud KE, et al. Depression, falls and risk of fracture in older women. Arch Intern Med 1999;159:484-90.
19. Tinetti ME, Williams CS. The effect of fall and injuries on functioning in community dwelling older persons. J Gerontol 1998;53A(2):M112-19.
20. Van Weel C, Vermeulen H, Van den Bosch W. Falls, a community care perspective. Lancet 1995;345:1549-51.
21. Marottoli RA, Berkman LF, Cooney LM. Decline in physical function following hip fracture. J Am Geriatr Soc 1992;40:861-6.
22. Ray W. Psychotropic drugs and injuries among the elderly: a review. J Clin Psychopharmacol. 1992;12(6):386-96.
23. Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994;331:821-7.
24. Wolf SL, Barnhart HX, Kutner NG, et al. Reducing frailty and falls in older persons: an investigation of tai chi and computerized balance training. J Am Geriatr Soc 1996;44:489-97.
25. Ray W, Taylor JA, Meador KG, et al. A randomized trial of a consultation service to reduce falls in nursing homes. JAMA 1997;278(7):557-62.
26. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis. I. Psychotropic drugs. J Am Geriatr Soc 1999;47:30-9.
27. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis. II. Cardiac and analgesic drugs. J Am Geriatr Soc 1999;47:40-50.
28. Morris JC, Rubin EH, Morris EJ, et al. Senile dementia of the Alzheimer's type: an important risk factor for serious falls. J Gerontol 1987;42(4):412-17.
29. Oleske DM, Wilson RS, Bernard BA, et al. Epidemiology of injury in people with Alzheimer's disease. J Am Geriatr Soc 1995;43(7):741-6.
30. Ray W, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316(7):363-9.
31. Cherin P, Colvez A, Deville de Periere G, et al. Risk of syncope in the elderly and consumption of drugs: a case-control study. J Clin Epidemiol 1996;50(3):313-20.
32. Quinn K, Baker MJ, Evans B. A population wide profile of prescription drug use in Saskatchewan, 1989. Can Med Assoc J 1992;146(12):2177-86.
33. Rojas-Fernandez C, Carver D., Tonks RS. Population trends in the prevalence of benzodiazepine use in the older population of Nova Scotia: a cause for concern? Can J Clin Pharmacol 1999;6(3):149-56.
34. Neutel CI, Hirdes JP, Maxwell CJ, et al. New evidence on benzodiazepine use and falls: the time factor. Age Ageing 1996;25:273-8.
35. Ray W, Griffin M, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989;262(23):3303-7.
36. Cumming RG, Miller P, Kelsey JL, et al. Medications and multiple falls in elderly people: the St. Louis OASIS study. Age Ageing 1991;20:455-61.
37. Sorock GS, Shimkin EE. Benzodiazepine sedatives and the risk of falling in a community-dwelling elderly cohort. Arch Intern Med. 1988;148:2441-4.
38. Herings R, Stricker BH, deBoer A, et al. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med 1995;155:1801-7.
39. Cumming RG, Klineberg RJ. Psychotropics, thiazides diuretics and hip fractures in the elderly. Med J Aust 1993;158:414-17.
40. Ray W, Griffin M, Malcom E. Cyclic antidepressants and the risk of hip fracture. Arch Intern Med 1991;151:754-6.
41. Liu B, Topper AK, Reeves RA, et al. Falls among older people: relationship to medication use and orthostatic hypotension. J Am Geriatr Soc 1995;43:1141-5.
42. Liu B, Anderson G, Mittmann N, et al. Use of selected serotonin reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998;351:1303-7.
43. Thapa P, Gideon P, Cost TW, et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998;339(13):875-82.
44. Gambassi G, Lapane KL, Sgadari A, et al. Elderly patients, use of antidepressants, and hip fractures [letter]. Lancet 1998;352:400-1.
45. Gordon J, Rojas-Fernandez C, Rockwood K. Practical solutions to polypharmacy problems in the elderly. Can J Diagn 1998;15(4):78-90.
46. Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997;61:331-9.
47. Sweet RA, Pollock BG. New atypical antipsychotics. Experience and utility in the elderly. Drugs Aging 1998;12(2):115-27.
48. Mungall D, White R. Aging and warfarin therapy [letter]. Ann Intern Med 1992;117(10):878-9.
49. Greenblatt DJ, Harmatz JS, Shapiro L, et al. Sensitivity to triazolam in the elderly. N Engl J Med 1991;324:1691-8.
50. Von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Psychotropic drug metabolism in old age. Principles and problems of assessment. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:1461-9.
51. LeCouter DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998;34(5):359-73.
52. Relling MV, Evans WE. Genetic polymorphisms of drug metabolism. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver, WA: Applied Therapeutics, 1992:7-1-32.
53. Shulman RW, Ozdemir V. Psythotropic meditations and cytochrome P450-2D6: pharmacokinetic considerations in the elderly. Can J Psychiatry 1997;42(suppl 1):4S-9.
54. Laurijssens BE, Greenblatt DJ. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet 1996;30(1):52-76.
55. Birge SJ. Can falls and hip fracture be prevented in frail older adults? J Am Geriatr Soc 1999;47:1265-6.
56. Robin DW, Hasan SS, Edeki T, et al. Increased baseline sway contributes to increased losses of balance in older people following triazolam. J Am Geriatr Soc 1996;44:300-4.
57. Liu YJ, Stagni G, Walden JG, et al. Thioridazine dose-related effects on biomechanical force platform measures of sway in young and old men. J Am Geriatr Soc 1998;46:431-7.
58. Gill HS, DeVane L, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997;17:377-89.
59. Caley CF. Extrapyramidal reactions and the selective serotonin reuptake inhibitors. Ann Pharmacother 1997;31:1481-9.
60. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects of oxidative drug metabolism. Clin Pharmacokinet 1997;32(suppl 1):1-21.
61. Bertz RJ, Grnanneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32(3):210-58.
62. Michalets E. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18(1):84-112.
63. Burt AM, ed. Cerebral cortex. In: Textbook of neuroanatomy. Philadelphia: WB Saunders, 1993:446-78.
64. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-76.
65. Meltzer HY, Ichikawa J, Chai B-L. Effect of selective serotonin (5-HT) reuptake inhibitors (SSRI) and tricyclic antidepressants on extracellular dopamine (DA). homovanillic acid (HVA) and 5-hydroxy-indoleacetic acid (5-HIAA) in rat striatum (STR) [abstr]. Soc Neurosci Abstr 1993;353(2):855.
66. Mayrent SL, Hennekens CH, Buring JE. Statistical association and cause-effect relationships. In: Mayrent SL, ed. Epidemiology in medicine. Boston/Toronto: Little, Brown, 1987:30-53, 243-323.